CY1111275T1 - Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου - Google Patents

Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου

Info

Publication number
CY1111275T1
CY1111275T1 CY20101101076T CY101101076T CY1111275T1 CY 1111275 T1 CY1111275 T1 CY 1111275T1 CY 20101101076 T CY20101101076 T CY 20101101076T CY 101101076 T CY101101076 T CY 101101076T CY 1111275 T1 CY1111275 T1 CY 1111275T1
Authority
CY
Cyprus
Prior art keywords
quinolin
crystalline form
carboxamide compound
crystalline
crystalline salts
Prior art date
Application number
CY20101101076T
Other languages
Greek (el)
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Publication of CY1111275T1 publication Critical patent/CY1111275T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20101101076T 2005-04-06 2010-11-25 Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου CY1111275T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
EP06740692A EP1874766B1 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Publications (1)

Publication Number Publication Date
CY1111275T1 true CY1111275T1 (el) 2015-08-05

Family

ID=37074104

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101076T CY1111275T1 (el) 2005-04-06 2010-11-25 Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου

Country Status (29)

Country Link
US (4) US7728004B2 (cg-RX-API-DMAC7.html)
EP (1) EP1874766B1 (cg-RX-API-DMAC7.html)
JP (2) JP5230407B2 (cg-RX-API-DMAC7.html)
KR (1) KR101322873B1 (cg-RX-API-DMAC7.html)
CN (1) CN101151264B (cg-RX-API-DMAC7.html)
AR (2) AR053208A1 (cg-RX-API-DMAC7.html)
AT (1) ATE479682T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006232129B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610657A2 (cg-RX-API-DMAC7.html)
CA (1) CA2603654C (cg-RX-API-DMAC7.html)
CY (1) CY1111275T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006016586D1 (cg-RX-API-DMAC7.html)
DK (1) DK1874766T3 (cg-RX-API-DMAC7.html)
EA (1) EA012115B1 (cg-RX-API-DMAC7.html)
ES (1) ES2350495T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100629T1 (cg-RX-API-DMAC7.html)
IL (1) IL186023A (cg-RX-API-DMAC7.html)
MA (1) MA29403B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012438A (cg-RX-API-DMAC7.html)
MY (1) MY151075A (cg-RX-API-DMAC7.html)
NO (1) NO339699B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ561900A (cg-RX-API-DMAC7.html)
PE (1) PE20061310A1 (cg-RX-API-DMAC7.html)
PL (1) PL1874766T3 (cg-RX-API-DMAC7.html)
PT (1) PT1874766E (cg-RX-API-DMAC7.html)
SI (1) SI1874766T1 (cg-RX-API-DMAC7.html)
TW (1) TWI377206B (cg-RX-API-DMAC7.html)
WO (1) WO2006108127A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708071B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
JP2010527357A (ja) * 2007-05-17 2010-08-12 セラヴァンス, インコーポレーテッド 腸の前処置のための運動促進剤
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
PT2225230T (pt) * 2007-12-07 2016-12-07 Vertex Pharma Formas sólidas de ácido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
SG11201912266QA (en) * 2017-07-31 2020-01-30 Theravance Biopharma R&D Ip Llc Methods of treating symptoms of gastroparesis using velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
WO2024061960A1 (en) 2022-09-20 2024-03-28 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) * 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
US5571820A (en) * 1992-11-20 1996-11-05 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7396933B2 (en) * 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
EA200702161A1 (ru) 2008-04-28
KR101322873B1 (ko) 2013-10-30
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
US20100197728A1 (en) 2010-08-05
NO20075574L (no) 2007-11-02
WO2006108127A3 (en) 2007-01-04
US20140256769A1 (en) 2014-09-11
MY151075A (en) 2014-03-31
JP2012153725A (ja) 2012-08-16
US9126994B2 (en) 2015-09-08
US7728004B2 (en) 2010-06-01
WO2006108127A2 (en) 2006-10-12
CN101151264A (zh) 2008-03-26
SI1874766T1 (sl) 2010-12-31
IL186023A0 (en) 2008-01-20
TWI377206B (en) 2012-11-21
CA2603654A1 (en) 2006-10-12
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
TW200643020A (en) 2006-12-16
PE20061310A1 (es) 2007-01-23
PT1874766E (pt) 2010-11-30
DE602006016586D1 (de) 2010-10-14
JP2008535848A (ja) 2008-09-04
MA29403B1 (fr) 2008-04-01
CA2603654C (en) 2014-05-27
MX2007012438A (es) 2007-12-05
IL186023A (en) 2011-09-27
AR053208A1 (es) 2007-04-25
HK1110866A1 (en) 2008-07-25
KR20070116988A (ko) 2007-12-11
EP1874766A2 (en) 2008-01-09
EA012115B1 (ru) 2009-08-28
NO339699B1 (no) 2017-01-23
ES2350495T3 (es) 2011-01-24
JP5230407B2 (ja) 2013-07-10
ATE479682T1 (de) 2010-09-15
US20160095849A1 (en) 2016-04-07
AU2006232129B2 (en) 2012-07-12
PL1874766T3 (pl) 2011-02-28
ZA200708071B (en) 2008-10-29
NZ561900A (en) 2010-12-24
HRP20100629T1 (hr) 2010-12-31
AU2006232129A1 (en) 2006-10-12
US20060229332A1 (en) 2006-10-12
AR110019A2 (es) 2019-02-13
CN101151264B (zh) 2011-07-06
BRPI0610657A2 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
CY1111275T1 (el) Κρυσταλλικη μορφη μιας ενωσης κινολινονης-καρβοξαμιδιου
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
CY1112366T1 (el) Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CY1113622T1 (el) Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2003075907A3 (en) Small molecule entry inhibitors
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли